Navigation Links
Cytogen Reports Publication Validating the Utility of its,Proprietary ProChart Database

PRINCETON, N.J.--(BUSINESS WIRE)--May 23, 2007 - Cytogen Corporation (NASDAQ: CYTO) today reported the publication of a review validating the utility of its ProChart(TM) database to help define the function of the WW domain-containing oxidoreductase (WWOX), an important tumor suppressor gene with known involvement in breast, prostate, lung, pancreatic, esophageal, and gastric cancers. The peer-reviewed article was published in the online edition (25 April 2007) of the Journal of Cellular Physiology as a Mini Review entitled "WWOX in biological control and tumorigenesis," by Rami I. Aqeilan and Carlo M. Croce, epub 25 April 2007. The publication focuses on the most recent progress in understanding the function of WWOX as a tumor suppressor.

WW and other modular domain families are known to be important in mediating many important protein-protein interactions. Because WWOX contains two WW domains, it was an ideal protein to analyze with ProChart, Cytogen's proprietary, comprehensive, experimentally validated database of protein-protein signaling interactions. Using ProChart, the authors were able to determine a number of novel WWOX-interacting proteins, including the transcription factors p73 and Ap-2 gamma, the latter of which is known to play a role in activating the expression of the epidermal growth factor, HER2 (erbB-2). The study also reviews the importance of the relationships between WWOX and critical proto-oncogenes such as ErbB4 and c-Jun.

Using ProChart to accelerate their studies of WWOX, in recent years researchers from Ohio State University have validated a number of key WWOX interactions and published several peer-reviewed journal articles. Prior to the application of ProChart, little was known about the specific biologic functions of WWOX protein expression or the signaling pathways that lead to its tumor suppressive effects. In the current publication, the authors specifically refer to the
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
2. Vion Pharmaceuticals Presents Clinical Data from a Phase II Trial of Cloretazine (VNP40101M) in Elderly AML Patients with Unfavorable Cytogenetics at EHA Meeting
3. New Data for Cytogens QUADRAMET Reported at Annual ASCO Meeting
4. Preclinical Data on Cytogens Technology to be Reported at the AACR Annual Meeting
5. New Clinical Data for Cytogens Quadramet and Prostacint to be Reported at Upcoming Major Medical Meetings
6. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
7. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
8. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
9. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
10. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
11. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
Post Your Comments:
(Date:7/29/2014)...   Health 2.0 announces Bernard Tyson , ... Eric Topol , Patrick Soon-Shiong , and Samsung,s ... 8th Annual Fall Conference this coming Sept. 21-24 in ... 2.0 is set to host the very first Wearable Tech ... Consumer Tech & Wearables: Powering Healthy Lifestyles. The ...
(Date:7/28/2014)... , July 28, 2014 Pharmacyclics, Inc. (the ... will hold a conference call and audio webcast to discuss ... NASDAQ Market closes on Thursday, July 31, 2014 at 4:30 ... Date: July 31, 2014 Time: 4:30 ... (877) 303-7908 International: (678) 373-0875 A webcast replay ...
(Date:7/28/2014)... 28, 2014 STAAR Surgical Company (NASDAQ: ... of implantable lenses and delivery systems for the eye ... and conference call with investors to July 31, 2014 ... Company rescheduled the release date and conference call to ... Hideo Watanabe , President of STAAR Japan, who ...
Breaking Medicine Technology:Kaiser Permanente CEO to Keynote Health 2.0 8th Annual Fall Conference 2Kaiser Permanente CEO to Keynote Health 2.0 8th Annual Fall Conference 3Pharmacyclics Announces Date of Conference call to discuss Financial Results for Second Quarter of 2014 2STAAR Surgical Moves Second Quarter Earnings Release and Conference Call One Day to July 31 2
... 2007 /PRNewswire/ --,The European Myeloma Platform (EMP) says ... plus the,steroid dexamethasone shows median survival of 35 ... two large randomized,controlled Phase III trials that enrolled ... worldwide. These updated results,were presented at the 11th ...
... ongoing phase I/II trial,of oncolytic HSV * Poster ... MARTINSRIED, Germany, June 29, 2007.--The biotech company,MediGene AG ... from the ongoing clinical trial of MediGene's cancer ... held by the European,Society for Medical Oncology. Out ...
Cached Medicine Technology:The European Myeloma Platform Reports New Survival data for,Revlimid Presented at the International Myeloma Workshop in Greece 2European Society for Medical Oncology (ESMO) Presents Data from the,Clinical Trial of MediGene's Cancer-Killing Virus in Press,Conference 2
(Date:7/29/2014)... 2014 According to the new ... (Swipe And Area), Material (Optical Prism, Pizeoelectric, Capacitive, ... Commercial Security and Banking & Finance), and Geography ... 2020", published by MarketsandMarkets, the global Fingerprint Sensors ... 2020, growing at a high CAGR of 16.8% ...
(Date:7/29/2014)... This Latest Guidebook for Conducting Pharma Clinical ... not only provided a comprehensive and thorough knowledge of ... drug registration but also introduced the practical operation how ... to use the Chinese trial venues to keep drug ... by step. , The audiences of this guidebook are ...
(Date:7/29/2014)... how best to treat patients after they,ve undergone surgery ... cancer comes back or provide men with additional radiation ... study from Thomas Jefferson University shows that ... a more informed decision. , "We are moving away ... Den, M.D., Assistant Professor of Radiation Oncology and Cancer ...
(Date:7/29/2014)... principle suitable to find out which preferences patients have ... health economic evaluations, some (primarily methodological) issues still need ... pilot project by the German Institute for Quality and ... Process (AHP), CA is the second method tested by ... outcome-specific results to an overall value , In ...
(Date:7/29/2014)... repeatedly shown that death rates rise in association with ... in the summer of 2003, for example, resulted in ... by Dr. Alex-andra Schneider at the Institute of Epidemiology ... of extreme temperatures on the number of deaths caused ... both high and low temperatures in the study. , ...
Breaking Medicine News(10 mins):Health News:Fingerprint Sensors Market by Type (Swipe And Area) Estimated to Reach $14.35 Billion by 2020 - New Report by MarketsandMarkets 2Health News:Fingerprint Sensors Market by Type (Swipe And Area) Estimated to Reach $14.35 Billion by 2020 - New Report by MarketsandMarkets 3Health News:Fingerprint Sensors Market by Type (Swipe And Area) Estimated to Reach $14.35 Billion by 2020 - New Report by MarketsandMarkets 4Health News:Pharma Clinical Trials Market in China: Authorities for Drug New Study Now Available at MarketReportsOnline.com 2Health News:Pharma Clinical Trials Market in China: Authorities for Drug New Study Now Available at MarketReportsOnline.com 3Health News:Pharma Clinical Trials Market in China: Authorities for Drug New Study Now Available at MarketReportsOnline.com 4Health News:Genomic analysis of prostate cancer indicates best course of action after surgery 2Health News:Determine patient preferences by means of conjoint analysis 2Health News:Determine patient preferences by means of conjoint analysis 3Health News:Determine patient preferences by means of conjoint analysis 4Health News:Mortality rates increase due to extreme heat and cold 2
... July 27 (HealthDay News) -- Intensive glucose-lowering treatment for ... of cardiovascular-related death and doctors need to be cautious ... suggests. Patients with type 2 diabetes are at ... widely used for these patients even though previous research ...
... News) -- Greater breast density is associated with an ... traits, new research says. In the study, published ... Journal of the National Cancer Institute , researchers used ... with breast cancer and a control group of 1,794 ...
... living in the United States particularly those who were ... spend for health care and are more likely to pay ... And while that disparity shrinks for naturalized Latinos ... large over time for non-citizen Latinos, the researchers found. ...
... protein that causes fireflies to glow, a Johns Hopkins team has ... the anticancer effects of the drug tamoxifen. The key is a ... breast cancer gene responds to the female hormone estrogen. In ... , the scientists show how a gene known as RET in ...
... 2011 A new study by York University researchers ... symptoms of chronic pain in women with fibromyalgia. ... effects of yoga on cortisol levels in women with ... by chronic pain and fatigue; common symptoms include muscle ...
... computed tomography (CT), researchers have identified two types of structural ... disease (COPD) that are associated with frequent exacerbations, or episodes ... the journal Radiology . COPD can damage both ... is a leading cause of death and illness worldwide. The ...
Cached Medicine News:Health News:Caution Urged in Intensive Treatment of Type 2 Diabetes 2Health News:Greater Breast Density May Raise Cancer Risk 2Health News:Big gap exists on health care spending between Latinos and whites, study finds 2Health News:Johns Hopkins researchers discover how some breast cancers alter their sensitivity to estrogen 2Health News:Yoga boosts stress-busting hormone, reduces pain: York U study 2Health News:CT shows changes in lungs associated with COPD flare-ups 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: